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Background: The validity of a cardiovascular risk self-screening method was assessed. The 
results obtained for self-measurement of blood pressure, a point-of-care system’s assessment of 
lipid profile and glycated hemoglobin, and a self-administered questionnaire (sex, age, diabetes, 
tobacco consumption) were compared with the standard screening (gold standard) conducted 
by a health professional.
Methods: Crossover clinical trial on a population-based sample from Girona (north-eastern 
Spain), aged 35–74, with no cardiovascular disease at recruitment. Participants were random-
ized to one of the two risk assessment sequences (standard screening followed by self-screening 
or vice versa). Cardiovascular risk was estimated with the Framingham-REGICOR function. 
Concordance between methods was estimated with the intraclass correlation coefficient (ICC). 
Sensitivity, specificity, and positive and negative predictive values were estimated, considering 
5% cardiovascular risk as the cutoff point. ClinicalTrials.gov Registration #NCT02373319. 
Clinical Research Ethic Committee of the Parc de Salut Mar Registration #2014/5815/I.
Results: The median cardiovascular risk in men was 2.56 (interquartile range: 1.42–4.35) 
estimated by standard methods and 2.25 (1.28–4.07) by self-screening with ICC=0.92 (95% 
CI: 0.90–0.93). In women, the cardiovascular risk was 1.14 (0.61–2.10) by standard methods 
and 1.10 (0.56–2.00) by self-screening, with ICC=0.89 (0.87–0.90). The sensitivity, specificity, 
and positive and negative predictive values for the self-screening method were 0.74 (0.63–0.82), 
0.97 (0.95–0.99), 0.86 (0.77–0.93), and 0.94 (0.91–0.96), respectively, in men. In women, these 
values were 0.50 (0.30–0.70), 0.99 (0.98–1), 0.81 (0.54–0.96), and 0.97 (0.95–0.99), respectively.
Conclusion: The self-screening method for assessing cardiovascular risk provided similar results 
to the standard method. Self-screening had high clinical performance to rule out intermediate 
or high cardiovascular risk.
Keywords: risk assessment, cardiovascular diseases, preventive medicine, public health, epi-
demiology, empowerment
Background
Cardiovascular diseases are the main cause of death in the developed world and are 
gaining importance in low-income countries.1 Nonetheless, a substantial fall in cardio-
vascular disease mortality has been observed in developed countries, approximately 
half of which has been attributed to cost-effective evidence-based treatments used 
in clinical cardiology and half to the crucial role of healthy diet, increased physical 
activity, and decreased consumption of tobacco and alcohol.2,3 These key drivers are 
increasingly recognized as being potentially powerful, rapid, equitable, and cost-saving.4
Currently, the first step in cardiovascular risk screening is the estimation of cardiovas-
cular risk using validated risk functions.5,6 This procedure, usually performed in primary 
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care settings under the supervision of health professionals, has 
limitations.5,7 For instance, there is a wide gap between expert 
recommendations and actual preventive  practice.8 Physicians 
have been found to have difficulty meeting the international 
standards even when they strongly believe that preventive 
care is important and that risk factors for cardiovascular 
disease can and should be reduced.9,10 Moreover, the current 
screening strategy may not reach young, healthy people, who 
are less likely to visit primary care settings11 but are also the 
main audience for the preventive message because cumulative 
exposure to cardiovascular risk factors over time precedes the 
clinical expression of cardiovascular diseases.
In addition, the trends in coronary heart disease mortal-
ity in the USA show a troubling contrast between the steep 
decrease recently observed in older populations and the small 
decreases in young populations.12 Although the low burden of 
cardiovascular diseases in younger populations would make 
it difficult to observe dramatic decreases, the implementa-
tion of preventive programs in young people is key to reduce 
the incidence at older ages. This paradigm may change if 
individuals can be empowered to assume a leading role in 
making decisions about their own health.13 Thus, the use of a 
self-screening method to assess cardiovascular risk may help 
to increase population awareness and shared responsibility 
for cardiovascular disease prevention.
To better address a key target population for the preventive 
message, the objective of the present study was to evaluate the 
validity of a cardiovascular risk self-screening method that 
includes self-measurement of blood pressure, a point-of-care 
assessment of lipid profile and glycated hemoglobin, and a 
self-administered questionnaire (sex, age, diabetes, tobacco 
consumption), compared with the standard screening (gold 
standard) conducted by a health professional.
Methods
In a randomized crossover clinical trial in the city of Girona 
and surrounding areas (northeastern Spain), individuals were 
randomly selected from the reference population. Those aged 
35–74 who did not present with cardiovascular diseases at 
baseline were included in the study. Participants were ran-
domly assigned to one of two cardiovascular risk screening 
sequences: standard screening followed by self-screening 
or vice versa. Both screening methods were performed the 
same day and included the eight variables used to estimate 
cardiovascular risk with the Framingham function, adapted 
and validated for the Spanish population14 using the stan-
dard methodology15: sex, age, systolic and diastolic blood 
pressure, total cholesterol, high-density lipoprotein (HDL) 
cholesterol, tobacco consumption, and diabetes. The only 
difference between the screening methods was the active 
role of the team of trained nurses in the standard screening 
and their minimal supervision of the self-screening, mainly 
related to blood capillary extraction and analysis.
We needed a sample size of 900 individuals to estimate 
a kappa index of 0.8 with 95% CI, considering that 65% of 
the reference population presented with low risk (<5%), 25% 
with intermediate risk (≥5% and <10%), and 10% with high 
risk (≥10%).6
All participants provided written informed consent 
before enrollment. The present study was approved by the 
Clinical Research Ethic Committee of the Parc de Salut Mar 
(CEIC-PSMAR, #2014/5815/I) and has been registered in 
ClinicalTrials.gov (#NCT02373319).
Blood pressure measurement
Blood pressure was measured with an automatic blood 
pressure monitor and a cuff adapted to upper arm perimeter 
(young, adult, obese) for each participant. After a 5-min 
rest, two measurements were taken, at least 2 minutes apart, 
and the lower value was recorded for the study. The cutoff 
points for hypertension followed the criteria in the Seventh 
Report of the Joint National Committee.16 The team of nurses 
performed these measures in the standard screening; in the 
self-screening, computer prompts guided the participants 
to independently measure and record their blood pressure.
Laboratory tests
To determine the lipid profile (total cholesterol, HDL cho-
lesterol, and triglycerides) and the glycated hemoglobin in 
the standard screening procedure, blood was withdrawn in 
<60 seconds after 10–14 h fasting. Serum sample aliquots 
were stored at –80°C. Total cholesterol and HDL cholesterol 
concentrations were determined by enzymatic and direct 
methodologies, respectively (ABX-Horiba, Montpellier, 
France). When triglycerides were <300 mg/dL, low-density 
lipoprotein cholesterol was calculated using the Friedewald 
formula. Glycated hemoglobin was determined by colo-
rimetry and latex agglutination procedures (ABX-Horiba). 
All analyses were performed in a central laboratory. When 
participants used the self-screening methodology, they 
performed a capillary blood analysis with the Cobas b101 
(Roche Diagnostics, Basel, Switzerland) point-of-care 
device under nurse supervision. Total and HDL choles-
terol (ApoB precipitation) were determined by enzymatic 
methods and glycated hemoglobin by latex agglutination 
procedure.
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Other variables collected
Both screening methods collected data on sex, age, educa-
tional level, tobacco consumption, and self-reported diabetes 
and related treatment with self-administered standard ques-
tionnaires. Although educational level was not required to 
estimate the cardiovascular risk, this variable was collected 
for the assessment of comparability of the two study groups. 
Diabetes was considered whenever an individual reported 
a history of the disorder, was being treated with insulin or 
oral antidiabetic treatments, or presented with a glycated 
hemoglobin ≥6.5%.17
A precision scale of easy calibration was used for weight 
measurement with participants in underwear. Height was 
measured with a standard measuring rod, with participants 
standing barefoot. Body mass index was determined as 
weight divided by squared height (kg/m2). Waist perimeter 
was also collected.
Statistical analysis
All analyses were stratified by sex. Categorical variables 
were presented as proportions and continuous variables as 
mean and SD or median and interquartile range when their 
distribution departed from normal.
To compare the results of the standard and the self- 
screening methods, the intraclass correlation coefficient 
(ICC) and kappa index were estimated for continuous (total 
and HDL cholesterol, glycated hemoglobin, systolic and 
diastolic blood pressure, cardiovascular risk) and categori-
cal variables (diabetes), respectively. We also estimated the 
kappa index in a sensitivity analysis, considering glycemia 
in the estimate of diabetes prevalence for the standard 
screening. Additionally, the concordance of lipid measure-
ments and glycated hemoglobin between the ABX-Horiba 
Pentra autoanalyzer® (standard screening) and the Cobas 
b101® point-of-care device (self-screening) was measured 
using the R2 coefficient of determination and Bland– Altman 
plots.18 We estimated the Pearson correlation between the 
two screening methods and compared the distribution in 
three cardiovascular risk categories (low <5%, intermediate 
≥5% and <10%, and high ≥10%) with chi-square tests. We 
described the intermediate/high-risk individuals identified 
with each strategy and estimated sensitivity, specificity, and 
the positive and negative predictive value, likelihood ratios of 
a positive and a negative test, diagnostic accuracy and odds 
ratio, Youden Index, and area under the receiver operator 
characteristics (ROC) curve at a cutoff point ≥5%.19
All the statistical analyses were performed with the R 
Statistical Package (R Foundation for Statistical Computing, 
Vienna, Austria; V.3.3.2).
Results
The present study included 937 individuals (52.3% women) 
with mean age of 50 years (SD=10) (Figure 1) and a response 
rate of 60%. No sex or age differences were found between 
participants and nonparticipants. Table 1 summarizes the 
main characteristics of the participants by sex and screen-
ing sequence. The additional variables, not used to estimate 
the cardiovascular risk, have been described using the same 
stratification in Table S1. The concordance between self-
screening and standard measures was high for all single 
variables studied (ICC≥0.86), except for glycated hemoglobin 
in women (ICC=0.72). The ICCs for cardiovascular risk were 
Figure 1 Flow chart of the participants in the ACRISC Study.
Abbreviation: CVR, cardiovascular risk; ACRISC, self-screening of cardiovascular risk.
Participants
N=937
Sequence A
N=473 (50.5%)
Men
N=225 (47.6%)
CVR <5%
N=182 (80.9%)
CVR <5%
N=236 (95.2%)
CVR <5%
N=178 (80.2%)
CVR <5%
N=228 (94.2%)
CVR ≥5% and <10%
N=13 (5.4%)
CVR ≥5% and <10%
N=37 (16.7%)
CVR ≥5% and <10%
N=12 (4.8%)
CVR ≥10%
N=0 (0.0%)
CVR ≥5% and <10%
N=37 (16.4%)
CVR ≥10%
N=6 (2.7%)
CVR ≥10%
N=7 (3.2%)
CVR ≥10%
N=1 (0.4%)
Women
N=248 (52.4%)
Men
N=222 (47.8%)
Women
N=242 (52.2%)
Sequence B
N=464 (49.5%)
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high in both men and women (0.92 [95% CI: 0.90–0.93] 
and 0.89 [0.87–0.90], respectively) (Table 2 and Figure 2). 
The results of the sensitivity analysis using glycemia for the 
standard screening yielded similar results (kappa index in 
men and in women: 0.94 and 0.86, respectively). Figures 
S1–S6 show the linear regression plots with the estimated R2 
and the Bland–Altman plots for total and HDL cholesterol 
and glycated hemoglobin levels as measured with the Pentra 
autoanalyzer® and Cobas b101® point-of-care device.
The standard and self-screening methods did not differ 
significantly in their classification of individuals by risk 
category (<5%, ≥5% and <10%, and ≥10%) with a kappa 
index =0.80 (Figure 3).
Self-screening of cardiovascular risk considering a cutoff 
point ≥5% showed high specificity and negative predictive 
value in both men and women. The likelihood ratio for a 
positive test (26.5 in men and 77.3 in women) indicated high 
probability of increased risk and the likelihood ratio for a 
negative test showed low probability of increased risk (0.27 
and 0.50, respectively). The diagnostic accuracy was also 
high, pointing out a marked proportion of correctly classified 
subjects. In addition, the estimates of diagnostic odds ratio, 
the Youden Index, and the area under the ROC curve showed 
a satisfactory discriminative power of the self-screening using 
the 5% cutoff point (Table 3).
Discussion
The estimation of cardiovascular risk is acknowledged as the 
first step in cardiovascular prevention, enabling application 
of the most efficient preventive strategy in each individual. 
Table 1 Participant characteristics by screening sequence
Variables Men Women
Sequence A 
(n=225)
Sequence B 
(n=222)
Sequence A 
(n=248)
Sequence B 
(n=242)
Age, mean (SD) 49 (10) 50 (10) 50 (10) 51 (11)
Educational level, n (%)
Primary school 45 (20.2) 53 (24.0) 56 (22.7) 51 (21.2)
High school 102 (45.7) 93 (42.1) 94 (38.1) 101 (41.9)
University 76 (34.1) 73 (33.0) 96 (38.9) 84 (34.9)
Smoking status, n (%)
Former smoker 86 (38.2) 79 (35.6) 70 (28.2) 71 (29.3)
Smoker 62 (27.6) 55 (24.8) 43 (17.3) 48 (19.8)
Systolic blood pressure (mmHg), mean (SD) 118 (16) 118 (15) 105 (15) 107 (16)
Diastolic blood pressure (mmHg), mean (SD) 78 (10) 78 (10) 71 (11) 71 (10)
Total cholesterol (mg/dL), mean (SD) 211 (37) 209 (40) 209 (39) 207 (36)
HDL cholesterol (mg/dL), mean (SD) 51 (11) 50 (11) 60 (14) 60 (13)
Diabetes, n (%) 19 (8.4) 24 (10.8) 9 (3.6) 13 (5.4)
Glycated hemoglobin (%), mean (SD) 5.5 (0.6) 5.6 (0.8) 5.5 (0.4) 5.5 (0.4)
Body mass index, mean (SD) 27.1 (4.2) 27.2 (4.1) 26.0 (5.0) 25.9 (4.6)
Abbreviation: HDL, high-density lipoprotein.
Table 2 Concordance between self-screening and standard measures needed to estimate cardiovascular risk, stratified by sex
Variables Men Women
Standard  
screening 
(n=447)
Self-screening 
(n=447)
Concordance  
(95% CI)
Standard  
screening 
(n=490)
Self-screening 
(n=490)
Concordance  
(95% CI)
Systolic blood pressure (mmHg), mean (SD) 118 (15) 118 (15) 0.86 (0.83–0.88)a 106 (16) 106 (16) 0.86 (0.83–0.88)a
Diastolic blood pressure (mmHg), mean (SD) 78 (10) 78 (10) 0.88 (0.86–0.90)a 71 (10) 73 (11) 0.87 (0.84–0.89)a
Total cholesterol (mg/dL), mean (SD) 210 (38) 200 (35) 0.86 (0.69–0.92)a 208 (37) 199 (34) 0.90 (0.74–0.95)a
HDL cholesterol (mg/dL), mean (SD) 51 (11) 52 (13) 0.91 (0.88–0.93)a 60 (13) 64 (15) 0.90 (0.76–0.95)a
Glycated hemoglobin, mean (SD) 5.6 (0.7) 5.7 (0.8) 0.91 (0.89–0.93)a 5.5 (0.4) 5.6 (0.5) 0.72 (0.67–0.76)a
Diabetes, n (%) 43 (9.6) 44 (9.8) 0.94b 22 (4.5%) 26 (5.3%) 0.87b
Cardiovascular risk, median (IQR) 2.56  
(1.42–4.35)
2.25  
(1.28–4.07)
0.92  
(0.90–0.93)a
1.14  
(0.61–2.10)
1.10  
(0.56–2.00)
0.89 (0.87–0.90)a
Notes: aIntraclass coefficient correlation; bkappa index.
Abbreviations: HDL, high-density lipoprotein; IQR, interquartile range.
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The innovative self-screening method proposed empowers 
the individual to measure and record the eight health vari-
ables (blood pressure, lipid profile, glycated hemoglobin, 
age, sex, tobacco consumption, diabetes) required to assess 
cardiovascular risk, with minimal supervision by a health 
professional. As results obtained were similar to the gold-
standard clinical method, healthy people who do not frequent 
clinical settings could increase their awareness and avoid 
preventable cardiovascular disease by conducting their own 
risk assessment at their convenience.
Empowerment for the prevention of 
cardiovascular diseases
Population empowerment is considered a key principle of 
health promotion by the World Health Organization.20 This 
concept emphasizes that all persons have strengths and 
Figure 2 Correlation between standard screening and self-screening measures of cardiovascular risk
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 providing appropriate resources enhances these strengths. 
This focus on lifestyle choices and personal responsibil-
ity has the potential to change how healthy people avoid 
preventable cardiovascular diseases as well as other chronic 
diseases and could indirectly promote choices of healthful 
activities. Recent reports have identified two approaches, 
improvement of individual patient skills and transfer of 
power and decision-making authority about interventions to 
patients, as effective empowerment strategies.21 The present 
study aimed to validate an easy procedure to self-collect 
eight variables of general interest (age, sex, tobacco con-
sumption, diabetes, systolic and diastolic blood pressure, 
and total and HDL cholesterol) to estimate cardiovascular 
risk. As in previous studies, lifetime risk increased expo-
nentially after 55 years of age according to the number of 
cardiovascular risk factors above the recommended levels.22 
Additionally, the combination of such variables in a car-
diovascular risk score (e.g., Framingham-REGICOR score 
validated for the Spanish population) provides valid infor-
mation about an individual’s 10-year cardiovascular risk.6 
General practitioners play an important role in the primary 
prevention of cardiovascular disease; however, mhealth 
has the potential to promote patient self-management, as 
a complement to the doctor’s intervention, and encourage 
greater participation in medical decision making. Our solu-
tion could be used together with usual office consultation 
and remote patient monitoring to implement a health care 
model including personalized health care delivery with 
an early diagnosis and treatment if needed. Although our 
self-screening method is not the first to be described in the 
literature,23,24 its novelty is the self-collection of objective 
variables (e.g., blood pressure, lipid profile, weight) with 
validated devices.
Prevention of cardiovascular disease in 
healthy individuals
Numerous innovations in health information technology 
are empowering individuals to assume a more active role in 
monitoring and managing their health and wellness, as well 
as their chronic conditions and therapeutic regimens.25 The 
effectiveness of self-management in chronic diseases has 
been analyzed through traditional education programs or, 
more recently, through mobile apps and other information 
and communication technologies.25–27 Regarding the latter, 
innovative approaches have been reported for overcoming 
obesity,28 encouraging regular physical activity29 and smok-
ing cessation,30 control of hypertension31 and dyslipidemia,32 
and treating diabetes mellitus.33 However, a major limitation 
of these innovative technologies is the absence of published 
evaluations. The present crossover clinical trial validates a 
new self-screening system that aims to empower individuals 
to assess their own cardiovascular risk. This device also could 
be used to estimate the risk of other chronic diseases such as 
cancer34–36 or cognitive decline37 in which the assessed comor-
bidities (hypertension, diabetes, obesity, dyslipidemia) play a 
crucial role. The added value of this validated procedure is the 
stratification of population risk, as users become aware about 
their own health and the most efficient strategies for preventing 
chronic diseases. Self-screening for cardiovascular risk yielded 
remarkable specificity and negative predictive values compared 
with the gold standard. In addition, there was high concordance 
between methods in the estimated cardiovascular risk category.
Table 3 Sensitivity, specificity, positive and negative predictive values, diagnostic accuracy and odds, Youden’s Index, and area under 
the ROC curve of self-screening compared with standard screening, stratified by sex
Clinical performance Self-screening of cardiovascular risk ≥5%
Men Women
Estimation 95% confidence interval Estimation 95% confidence interval
Observed prevalence 0.19 0.16–0.23 0.05 0.03–0.08
Estimated prevalence 0.17 0.13–0.20 0.03 0.02–0.05
Sensitivity, % 0.74 0.63–0.82 0.50 0.30–0.70
Specificity, % 0.97 0.95–0.99 0.99 0.98–1.00
Positive predictive value, % 0.86 0.77–0.93 0.81 0.54–0.96
Negative predictive value, % 0.94 0.91–0.96 0.97 0.95–0.99
Likelihood ratio of a positive test 26.5 14.2–49.4 77.3 23.5–254.6
Likelihood ratio of a negative test 0.27 0.19–0.39 0.50 0.34–0.74
Diagnostic accuracy 0.93 0.90–0.95 0.97 0.95–0.98
Diagnostic odds ratio 97.4 44.3–214.3 153.7 39.0–605.4
Youden’s Index 0.71 0.58–0.81 0.49 0.28–0.70
Area under the ROC curve 0.85 0.81–0.90 0.75 0.65–0.84
Abbreviation: ROC, receiver operator characteristics.
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Limitations
Risk estimation is considered the best tool to prioritize primary 
prevention strategies.5,8 Our crossover clinical trial aimed to 
validate a new self-screening method in a population-based 
sample that covered a very wide range of cardiovascular risk. 
Participants were randomized to one of two sequences of risk 
assessment (i.e., the current gold standard followed by self-
screening or vice versa) and all four risk measurements (sys-
tolic and diastolic blood pressure, total and HDL cholesterol) 
were collected with both methodologies. Selection bias may 
affect the present study, but is likely to be modest because it 
was population-based and participants were not selected on the 
basis of cardiovascular risk. In addition, the low cardiovascular 
risk traditionally observed in Mediterranean women38 and also 
reflected in our analysis may explain the low sensitivity of the 
self-screening (50%) to rule out intermediate or high cardiovas-
cular risk. Despite the availability of a cardiovascular risk score 
with no laboratory and blood pressure determinations that has 
been validated for the Spanish population,39 we preferred to 
validate the self-screening procedure using the more accurate 
Framingham-REGICOR cardiovascular risk chart.6,14 The aim 
of the study was to assess the validity of a cardiovascular risk 
self-screening method by comparing the results with a gold 
standard (current clinical practice). However, we did not test 
whether the self-screening had an effect on health outcomes. 
Further randomized clinical trials should be performed to 
answer this question. Finally, although our aim is to empower 
individuals to monitor their cardiovascular health, preferably 
at home, the blood capillary extraction and analysis must be 
supervised by a health care professional. Thus, the present 
version of the system must be implemented at a centralized 
location that is readily accessible to the target population (e.g., 
pharmacies, primary health care settings).
Future directions
This self-screening system encourages users to take respon-
sibility for their own health and well-being. Although health 
care professionals are ideally positioned to provide advice 
and education on risk factors and lifestyle modifications to 
people living with chronic conditions, a large part of the 
healthy population seldom visits a health care provider. Thus, 
a validated self-management system based on objective 
measurements empowers healthy people to avoid preventable 
cardiovascular and other chronic diseases. Our innovative 
method makes it possible to expand screening coverage to 
healthy populations, encouraging personal empowerment 
and increasing self-awareness of individual risk. A feedback 
strategy could be combined with tailored lifestyle recom-
mendations to improve adherence to healthier habits and 
encourage effective disease prevention strategies.
Conclusion
The self-screening method for assessing cardiovascular risk 
provided similar results to the standard method. In addition, 
this innovative system showed high clinical performance to 
rule out intermediate or high cardiovascular risk (i.e., ≥5%).
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Supplementary materials
Table S1 Participant characteristics (additional variables) by screening sequence
Variables Men Women
Sequence A  
(n=225)
Sequence B  
(n=222)
Sequence A 
(n=248)
Sequence B 
(n=242)
Family history, n (%)
Coronary death 22 (9.8) 30 (13.5) 26 (10.5) 27 (11.2)
Stroke 37 (16.4) 42 (18.9) 47 (19.0) 56 (23.1)
Intermittent claudication 6 (2.7) 14 (6.3) 13 (5.2) 20 (8.3)
Waist circumference (cm), mean (SD) 98.9 (7.0) 99.1 (6.8) 101.1 (9.2) 100.4 (8.1)
LDL cholesterol (mg/dL), mean (SD) 136 (38) 137 (39) 133 (33) 130 (31)
Triglycerides (mg/dL), mean (SD) 91 (66–119) 89 (66–123) 69 (54–98) 74 (56–101)
Non-HDL cholesterol (mg/dL), mean (SD) 160 (37) 159 (39) 149 (37) 147 (34)
Total/HDL cholesterol, mean (SD) 4.3 (1.0) 4.3 (1.2) 3.6 (1.0) 3.6 (0.9)
LDL/HDL cholesterol, mean (SD) 2.7 (0.9) 2.8 (1.0) 2.3 (0.8) 2.3 (0.7)
Triglycerides/HDL cholesterol, mean (SD) 2.3 (1.6) 2.3 (1.9) 1.5 (1.1) 1.5 (1.0)
Glycemia (mg/dL), mean (SD) 93 (87–100) 94 (89–101) 89 (83–96) 89 (83–96)
History of diabetes, n (%) 15 (6.7) 22 (10.0) 7 (3.1) 12 (5.5)
History of hypertension, n (%) 60 (27.0) 68 (31.2) 36 (14.8) 42 (17.4)
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Figure S1 Linear regression analysis for total cholesterol (mg/dL) by sex.
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Figure S2 Bland–Altman plot for total cholesterol (mg/dL).
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Figure S3 Linear regression analysis for HDL cholesterol (mg/dL) by sex.
Abbreviation: HDL, high-density lipoprotein.
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Figure S4 Bland–Altman plot for HDL cholesterol (mg/dL).
Abbreviation: HDL, high-density lipoprotein.
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Figure S5 Linear regression analysis for glycated hemoglobin (%) by sex.
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Figure S6 Bland–Altman plot for glycated hemoglobin (%).
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